Clinical Trial: Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07638787) titled 'Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL' on May 28.

Brief Summary: This is a Phase I/II study. The Phase I part will evaluate the safety and tolerability of sonrotoclax in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), using a standard 3+3 dose-escalation design, to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). The Phase II part will assess the efficacy of the combination regimen in patients with previously untreated LBCL with high BCL2 expression or MYC/BCL2 rearrangements.

Study Start Date: June 15

Stud...